Juan Duque, MD
Internal Medicine · Miami, FLNPI 1124105846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,511 and has fallen 81.9% since, to $274 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$899
- GSK$641
- Lilly USA, LLC$566
- Novo Nordisk$559
- AstraZeneca$402
- Boehringer Ingelheim$365
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,441100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 59 | $899 |
| GSK | 40 | $641 |
| Lilly USA, LLC | 37 | $566 |
| Novo Nordisk | 29 | $559 |
| AstraZeneca | 17 | $402 |
| Boehringer Ingelheim | 18 | $365 |
| AbbVie(2 entities) | 29 | $343 |
| Johnson & Johnson | 15 | $252 |
| Exact Sciences | 10 | $246 |
| Actelion Pharmaceuticals US, Inc. | 13 | $227 |
| Amgen(2 entities) | 7 | $134 |
| Vifor Pharma, Inc. | 1 | $123 |
| Phathom Pharmaceuticals, Inc. | 1 | $109 |
| Sanofi-aventis U.S. LLC | 6 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $81 |
| Merck | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Novartis | 2 | $40 |
| Pfizer | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $25 |
| Abbott | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Insmed, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,443 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $90,766 |
| MounjaroTirzepatide | 50 | $71,520 |
| EliquisApixaban | 28 | $48,157 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| OzempicSemaglutide | 35 | $43,278 |
| FarxigaDapagliflozin Propanediol | 33 | $39,436 |
| JanuviaSitagliptin Phosphate | 40 | $36,392 |
| TradjentaLinagliptin | 30 | $34,818 |
| XareltoRivaroxaban | 12 | $16,735 |
| VascepaIcosapent Ethyl | 14 | $15,143 |
| MyrbetriqMirabegron | 15 | $11,624 |
| SynthroidLevothyroxine Sodium | 29 | $3,863 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,981 |
| HumalogInsulin Lispro | 19 | $2,196 |
| Rosuvastatin Calcium | 153 | $1,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $365 | $125,58488 claims |
| Lilly USA, LLCMounjaro, Humalog | $566 | $73,71769 claims |
| PfizerEliquis | $37 | $48,15728 claims |
| Novo NordiskOzempic | $559 | $43,27835 claims |
| AstraZenecaFarxiga | $402 | $39,43633 claims |
| MerckJanuvia | $45 | $36,39240 claims |
| Johnson & JohnsonXarelto | $252 | $16,73512 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $11,62415 claims |
| AbbVieSynthroid | $343 | $3,86329 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $1,209141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.